Hospira — Investor Day (September 2009)
37 slides from Hospira's investor day presentation, Sep 17, 2009
Slide 1: Hospira: Fueling Growth
Hospira Fueling Growth — a
Slide 2: Thomas E. Werner, SVP Finance and CFO
Thomas E. Werner Senior Vice President, Finance, and Chief Financial Officer
Slide 3: Safe Harbor
Safe Harbor This event contains forward-looking statements within the meaning of the federal securities laws. Hospira intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the federal securities laws. In some cases, you can identify th
Slide 4: Agenda
Agenda Financial Highlights First-Half 2009 Project Fuel Long-Term Growth Summary
Slide 5: Significant Progress
Significant Progress * Gross Margin, Operating Income and EPS are non-GAAP results for 2005-2009E. Non-GAAP measures are reconciled to GAAP measures in the Appendix. ** 2009 estimate is at the mid-point of the guidance range. Net Sales ($B) Gross Margin %* Operating Income %* Earnings Per Share* $2.
Slide 6: Focus on Free Cash Flow
Focus on Free Cash Flow FCF % of sales Free cash flow 10% 7% 12% Free cash flow is defined as cash flow from operations less capital expenditures. 2009 estimate is at the mid-point of the guidance range. 12% 13% Free Cash Flow FCF % Sales $100 $200 $300 $400 $500 2005 2006 2007 2008 2009E
Slide 7: Reducing Debt
Reducing Debt $375MM due $500MM due $400MM due $550MM due $2.1B debt Paid $300MM Issued $250MM 6-year notes 2007 2008 2009 2012 2014 2017 2010 2015 $250MM due $2.6B debt Paid $400MM $2.12B debt Paid $100MM
Slide 8: Improving ROIC
12% 13% 16% Improving ROIC * 2009 estimate is at the mid-point of the guidance range. Return % 21% FY05 FY06 1Q07 2Q07 3Q07 4Q07 1Q08 2Q08 3Q08 4Q08 1Q09 2Q09 FY09E
Slide 9: Capital Allocation
* Excludes Mayne Pharma acquisition, largely funded by debt. Capital Allocation $1.2B $125MM $550MM $300MM $600MM $2.8B Near Term 2009-2010 Maintain investment-grade rating Establish desired liquidity levels ~120% x EBITDA $375MM paydown due March 2010 Consider repurchase of debt or stock in 2011 20
Slide 10: Outperforming S&P Healthcare and Broader U.S. Market Indices
Outperforming S&P Healthcare and Broader U.S. Market Indices HSP S&P 500 Dow Jones Ind. Avg. S&P Healthcare HSP 50.9% SPX (7.4%) HCX (1.4%) DJIA (6.3%) -60% -40% -20% 0% 20% 40% 60% 80% 100% 7/31/04 1/31/05 7/31/05 1/31/06 7/31/06 1/31/07 7/31/07 1/31/08 7/31/08 1/31/09 7/31/09
Slide 11: First-Half
F I R S T - H A L F 2 0 0 9
Slide 12: First-Half 2009 Highlights
First-Half 2009 Highlights Delivered strong net sales despite a difficult economic environment Enhanced GPO contract awards Made significant progress on Project Fuel Continued advancement in biogenerics Paid down debt Increased annual guidance
Slide 13: First-Half 2009 Financial Summary
First-Half 2009 Financial Summary Net Sales*: grew 7% Operating income**: increased 10% Cash balance at June 30, 2009: $609MM Free cash flow**: 9% * On a constant-currency basis. ** Non-GAAP measure.
Slide 14: New Product Launches
New Product Launches Oxaliplatin Launched in August 2009 Sold through both hospital and alternate site channels Current erosion rate 55-65% High-Dose Heparin Launched in September 2009 Limited competition in market
Slide 15: Updates to 2009 Guidance
Updates to 2009 Guidance N/A Operating Margin %* 39.5% - 40.0% Gross Margin %* $2.70 - $2.75 Diluted EPS* $565 - $615MM Cash Flow from Ops Other 4% - 6% GLOBAL 4% - 6% 4% - 6% Americas SIP Revenue (Constant Currency) 18.0% - 19.0% Operating Margin %* 39.5% - 40.5% Gross Margin %* $2.80 - $2.85 Dilut
Slide 16: Benchmark Analysis
Benchmark Analysis Identified opportunities Understood constraints Ranked progress against pharma and device peers Analyzed progress to date Completed benchmarking : Our gross margin* improved over 1000 basis points Our operating income* improved 400 basis points Despite these efforts, our performan
Slide 17: Project Fuel Initiatives
Project Fuel Initiatives Optimize finance organization Reduce procurement costs Optimize IT spend 1 ® Hospira
Slide 18: Project Fuel Financial Summary
Project Fuel Financial Summary Eliminate 40% of list numbers (SKUs) Reduce workforce by 10% Streamlining Complexity reduction Operating income impact 2009: $8 - $10MM 2010: $70 - $80MM 2011: $110 - $140MM One-time costs $140 - $160MM
Slide 19: Simplify Product Line: Complexity Reduction
S A L E S Low High Low High B A D C P R O F I T A B I L I T Y “Core” product offering Eliminate list numbers and migrate to quadrant A or B Simplify Product Line Selectively eliminate list numbers and move to quadrant A Improve profitability of underperforming asset Vision - “Zero-complexity” focus
Slide 20: Optimize Finance Organization
Optimize Finance Organization Streamline planning and forecasting process Separate finance from accounting activities Reduce complexity, increase automation Centralize activities into shared service environment, including outsourcing Costs as a % of sales 1.2% 1.9% Average Hospira
Slide 21: Optimize IT Spend
Optimize IT Spend Increase outsourcing Optimize software and supplies Rationalize applications Costs as a % of sales 2.5% 3.0% Average Hospira
Slide 22: Progress to Date
Progress to Date Identified approximately 50% of our 7,000+ SKUs that can be eliminated over time Have eliminated 15% Sold Critical Care business to ICU Medical Notified over 50% of the impacted workforce Tracking to commitments
Slide 23: Financial Goals: Continued Growth
FINANCIAL GOALS Continued Growth
Slide 24: Delivering Financial Goals
Delivering Financial Goals Low to mid double digits 11% - 13% Annual EPS Growth* High single digits 5% - 7% Annual Revenue Growth Improve by 35% N/A Operating Income* per Employee Low 20s (%) 18% - 19% Operating Margin* Over 20% 16% ROIC Low 40s (%) 39.5% - 40.5% Gross Margin* 2011E 2009E * Gross Ma
Slide 25: Risks and Upsides
Risks and Upsides Market improvement Little to no appreciable near-term recovery in capital markets Accelerated regulatory drug approvals Major drug launch delays Favorable resolution of Paragraph IV legal actions Unfavorable resolution of Paragraph IV legal actions Greater-than-expected benefit fro
Slide 26: Hospira Recap YTD2009
Hospira Recap YTD2009 Strong first half with solid performance in both SIP and MMS Launched first Paragraph IV - Oxaliplatin Launched high-dose Heparin Increased GPO contract awards with Premier and MedAssets Reduced debt by $50MM Tracking to save $8 - $10MM from Project Fuel efforts
Slide 27: Hospira Financial Summary
Hospira Financial Summary Launching new products with significant opportunity Leveraging cost structure Improving gross and operating margins Increasing R&D throughput Managing working capital Generating significant cash flow Focusing on driving shareholder value
Slide 28: Hospira: Fueling Growth
Hospira Fueling Growth — a
Slide 29: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations Net Sales The company expects net sales on a reported basis to be slightly up for full-year 2009. There have been no changes to the company's expectations with respect to foreign exchange assumptions since the second quarter 2009 conference call. Reconciliation of GA
Slide 30: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations Reconciliation of Historical Free Cash Flow to GAAP Measures: 2008 2007 2006 2005 Cash Flow from Operating Activities - GAAP 584 $ 551 $ 424 $ 571 $ Adjustments: Capital Expenditures (164) (211) (235) (256) Free Cash Flow (1) - Non-GAAP 420 $ 340 $ 189 $ 315 $ (1) Fr
Slide 31: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations Six months ended June 30, 2009 adjustments and Reconciliation of GAAP to Non-GAAP Financial Measures: Gross Profit (1) Income From Operations Net Income Diluted EPS GAAP financial measures 665.8 $ 205.8 $ 191.0 $ 1.18 $ Specified items: Project Fuel charges (A) 4.8 7
Slide 32: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations Hospira, Inc. Reconciliation of Condensed Consolidated Statements of Income (Unaudited) (dollars and shares in millions, except per share amounts) % Change vs. Prior Year GAAP Adjustments Adjusted GAAP Adjustments Adjusted GAAP Adjusted Net sales 3,629.5 $ - $ 3,629.
Slide 33: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations Hospira, Inc. Reconciliation of Condensed Consolidated Statements of Income (Unaudited) (dollars and shares in thousands, except per share amounts) % Change vs. Prior Year GAAP Adjustments Adjusted GAAP Adjustments Adjusted GAAP Adjusted Net sales 3,436,238 $ - $ 3,4
Slide 34: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations GAAP Adjustments Adjusted GAAP Adjustments Adjusted GAAP Adjusted Net sales 2,527,714 $ - $ 2,527,714 $ 2,457,588 $ - $ 2,457,588 $ 2.9 2.9 Net sales to Abbott Laboratories 160,791 - 160,791 169,108 - 169,108 (4.9) (4.9) Total Net Sales 2,688,505 - 2,688,505 2,626,69
Slide 35: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations GAAP Adjustments Adjusted GAAP Adjustments Net sales 2,457,588 $ - $ 2,457,588 $ 2,465,052 $ - $ Net sales to Abbott Laboratories 169,108 - 169,108 179,984 - Total Net Sales 2,626,696 - 2,626,696 2,645,036 - Cost of products sold 1,777,640 (48,722) A 1,728,918 1,858,
Slide 36: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations 2003* GAAP Adjustments Adjusted GAAP GAAP Adjusted** Net sales 2,465,052 $ - $ 2,465,052 $ 2,400,228 $ 2.7 2.7% Net sales to Abbott Laboratories 179,984 - 179,984 223,509 (19.5) (19.5) Total Net Sales 2,645,036 - 2,645,036 2,623,737 0.8 0.8% Cost of products sold 1,8
Slide 37: GAAP to Non-GAAP Reconciliations
GAAP to Non-GAAP Reconciliations The tables on the previous five slides reconcile the most comparable U.S. Generally Accepted Accounting Principles (GAAP) measures to the non-GAAP financial and operating measures presented in Hospira’s current presentations to the investment community. “Adjusted Gro